1426 related articles for article (PubMed ID: 9915665)
1. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
2. Management of dyslipidemia in adults with diabetes.
Haffner SM
Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance syndrome and type 2 diabetes mellitus.
Erkelens DW
Am J Cardiol; 2001 Oct; 88(7B):38J-42J. PubMed ID: 11595198
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
5. Treatment of diabetic dyslipidemia.
Garg A
Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
[TBL] [Abstract][Full Text] [Related]
6. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
7. Triglyceride as a risk factor for coronary artery disease.
Gotto AM
Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol and atherosclerosis: a contemporary perspective.
Kashyap ML
Ann Acad Med Singap; 1997 Jul; 26(4):517-23. PubMed ID: 9395824
[TBL] [Abstract][Full Text] [Related]
11. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
12. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
Goldberg RB
Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
[TBL] [Abstract][Full Text] [Related]
13. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering therapy in diabetes mellitus.
Niemeijer-Kanters SD; Banga JD; Erkelens DW
Neth J Med; 2001 May; 58(5):214-22. PubMed ID: 11414234
[TBL] [Abstract][Full Text] [Related]
15. Current, new and future treatments in dyslipidaemia and atherosclerosis.
Chong PH; Bachenheimer BS
Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension.
Rubies-Prat J; Ordóñez-Llanos J; Martin S; Blanco-Vaca F; Molina L; Goday A; Pedro-Botet J
Clin Exp Hypertens; 2001 Aug; 23(6):489-500. PubMed ID: 11478431
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus.
Laakso M
J Diabetes Complications; 1997; 11(2):137-41. PubMed ID: 9101400
[TBL] [Abstract][Full Text] [Related]
19. Intensive lipid-lowering strategy in patients with diabetes mellitus.
Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
[TBL] [Abstract][Full Text] [Related]
20. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Davignon J
Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
